To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes

Inclusion criteria

• Male or nonpregnant females aged at least 18 years with chronic open angle glaucoma or ocular hypertension in both eyes
• Subject requires treatment of both eyes and is able to discontinue use of all ocular hypotensive medication(s) or switch ocular hypotensive medications and undergo appropriate washout period.
• Adequate wash-out period prior to baseline of any ocular hypotensive medication.
• Baseline (Day 0/hour 0) pressure ≥ 22 mm Hg and ≤ 34 mm Hg in each eye and any asymmetry of pressure between the eyes no greater than 5 mm Hg.
• Baseline best corrected visual acuity equivalent to 20/200 or better in each eye

Exclusion criteria

• Females who are pregnant, breast feeding, or planning a pregnancy.
• Females of childbearing potential who do not agree to utilize an adequate form of contraception
• Current, or past history of, severe hepatic or renal impairment
• Current, or history within two months prior to baseline of, significant ocular disease, e.g., corneal edema, uveitis, ocular infection, or ocular trauma in either eye
• Current corneal abnormalities that would prevent accurate readings with the Goldmann applanation tonometer
• Functionally significant visual field loss
• Contraindication to brinzolamide or sulfonamide therapy or known hypersensitivity to any component of brinzolamide or sulfonamide therapy
• Use at any time prior to baseline of an intraocular corticosteroid implant
• Use within one week prior to baseline of contact lens
• Use within two weeks prior to baseline of: 1) topical ophthalmic corticosteroid, or 2) topical corticosteroid
• Use within one month prior to baseline of: 1) systemic corticosteroid or 2) high-dose salicylate therapy
• Use within six months prior to baseline of intravitreal or subtenon injection of ophthalmic corticosteroid
• Having undergone within six months prior to baseline any other intraocular surgery (e.g., cataract surgery)
• Having undergone within twelve months prior to baseline refractive surgery, filtering surgery, or laser surgery for pressure reduction